HSCS (HeartSciences) EPS (Basic) : $-10.21 (TTM As of Jan. 2025)

View and export this data going back to 2022. Start your Free Trial

What is HeartSciences EPS (Basic)?

HeartSciences's basic earnings per share (Basic EPS) for the three months ended in Jan. 2025 was $-2.57. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2025 was $-10.21.

HeartSciences's EPS (Diluted) for the three months ended in Jan. 2025 was $-2.57. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was $-10.21.

HeartSciences's EPS without NRI for the three months ended in Jan. 2025 was $-2.57. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2025 was -10.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

HeartSciences EPS (Basic) Historical Data

The historical data trend for HeartSciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartSciences EPS (Basic) Chart

HeartSciences Annual Data

Trend

Apr20

Apr21

Apr22

Apr23

Apr24

EPS (Basic)

-47.39

-30.49

-59.52

-80.00

-19.00

HeartSciences Quarterly Data
	Apr20	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
EPS (Basic)	Get a 7-Day Free Trial												-3.01	-2.73	-2.64	-2.27	-2.57

HeartSciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

HeartSciences's Basic EPS for the fiscal year that ended in Apr. 2024 is calculated as

Basic EPS (A: Apr. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.605	-	0)	/	0.353
	=	-18.71

HeartSciences's Basic EPS for the quarter that ended in Jan. 2025 is calculated as

Basic EPS (Q: Jan. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.536	-	0)	/	0.986
	=	-2.57

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.21

HeartSciences (NAS:HSCS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

HeartSciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of HeartSciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

HeartSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeartSciences Inc (NAS:HSCS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website

https://www.heartsciences.com

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

Executives

David R. Wells	director	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent	director	750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz	director, officer: See Remarks	3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson	officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson	director, officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092